Skip to Main Content
Contribute Try STAT+ Today

The Food and Drug Administration on Thursday outlined the agency’s plans for weighing submissions for new opioid approvals, following criticism that the agency has been too lax in giving the green light to powerful new painkillers and calls for it to halt the approval of new opioids.

In a draft guidance, the agency said that it planned to start comparing the safety and effectiveness of opioid medications up for approval against those of painkillers — both opioids and other types — already on the market. If the guidelines are finalized, the FDA will also start considering the broader public health consequences of approving a drug, including whether its features make it more likely to be accidentally taken by children, for example, or if they mean it’s less likely to be misused.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.